{"id":"NCT00301366","sponsor":"Grifols Therapeutics LLC","briefTitle":"The Safety and Tolerability of Alpha-1 Modified Process (MP) In Subjects With Alpha-1-antitrypsin (AAT) Deficiency","officialTitle":"Multi-center, Open-label Trial to Evaluate the Safety and Tolerability of Alpha-1 MP in Subjects With Alpha-1-antitrypsin (AAT) Deficiency","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-06","primaryCompletion":"2007-03","completion":"2007-03","firstPosted":"2006-03-10","resultsPosted":"2014-08-19","lastUpdate":"2014-08-19"},"enrollment":38,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Alpha 1-Antitrypsin Deficiency"],"interventions":[{"type":"DRUG","name":"alpha-1 proteinase inhibitor (human)","otherNames":["Prolastin","Alpha-1 antitrypsin (AAT)","BAY x 5747","BAY 10-5233","TAL-05-00007"]}],"arms":[{"label":"Alpha-1 Proteinase Inhibitor (Human), modified process","type":"EXPERIMENTAL"}],"summary":"The purpose of this clinical study is to assess the safety and tolerability of Alpha-1 MP in adult Alpha1-antitrypsin deficient patients.","primaryOutcome":{"measure":"Treatment-emergent Adverse Events (TEAEs) Defined as Any Adverse Event (AE) Occurring During or After the Start of the First Study Drug Infusion.","timeFrame":"24 weeks","effectByArm":[{"arm":"Alpha-1 MP Treatment Group","deltaMin":38,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":3},"locations":{"siteCount":10,"countries":["United States","United Kingdom"]},"refs":{"pmids":["3494198","7028785","6169740"],"seeAlso":["http://www.alphaone.org","http://www.alphanet.org"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":38},"commonTop":["Nausea","Upper respiratory tract infection","Urinary tract infection","Chest pain","Influenza like illness"]}}